Pomanox (Pomegranate Extract)

Pomanox is a standardized pomegranate extract concentrated in punicalagins and ellagic acid, bioactive polyphenols that exert antioxidant and anti-inflammatory effects by scavenging reactive oxygen species and modulating NF-κB signaling. These mechanisms support cardiovascular function, endurance performance, and skin aging markers at the gene expression level.

Origin & History

Pomanox is a branded pomegranate extract derived from Punica granatum L. fruit cultivated in Mediterranean Spain using sustainable farming. It is produced via the patented Pure-Hydro Process, an eco-friendly aqueous extraction method using only ultrapure water as solvent, which concentrates water-soluble polyphenols while eliminating 99% of mineral residues.

Historical & Cultural Context

Pomegranate (Punica granatum) has historical use in traditional Mediterranean medicine systems, though specific traditional applications for Pomanox are not detailed. The modern extraction process is described as mimicking a 'tea bag infusion,' suggesting continuity with traditional water-based preparations.

Health Benefits

• Cardiovascular health support (evidence quality: preliminary - no specific RCTs detailed) • Skin anti-aging effects through gene expression modulation (evidence quality: preliminary - based on in vitro study) • Enhanced endurance and stamina (evidence quality: preliminary - clinical studies mentioned but no PMIDs provided) • Cognitive function support (evidence quality: preliminary - studies referenced without specific details) • Gut health benefits via urolithin metabolite production (evidence quality: preliminary - mechanism described but no clinical trials cited)

How It Works

Pomanox exerts its effects primarily through punicalagins and their metabolite urolithin A, which inhibit NF-κB transcription factor activity, thereby reducing pro-inflammatory cytokine production including TNF-α and IL-6. Its polyphenolic compounds directly scavenge reactive oxygen species and upregulate endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, reducing oxidative stress in vascular endothelial cells. Additionally, punicalagins modulate matrix metalloproteinase (MMP-1 and MMP-3) gene expression in dermal fibroblasts, contributing to extracellular matrix preservation relevant to skin aging.

Scientific Research

Euromed reports over 15 studies on Pomanox supporting various health benefits, though specific PubMed PMIDs and trial details are not provided in available sources. The only identified study is a preclinical investigation on skin aging showing gene expression changes, but no human randomized controlled trials with detailed outcomes are documented for this specific branded extract.

Clinical Summary

Clinical evidence for Pomanox is preliminary and largely derived from small-scale studies. A cited clinical study suggests improvements in endurance and stamina, though specific sample sizes and effect magnitudes have not been broadly published in peer-reviewed literature at scale. In vitro research demonstrates modulation of MMP gene expression in skin fibroblasts, supporting anti-aging claims but lacking confirmatory human RCT data. Cardiovascular benefits are mechanistically plausible given pomegranate's broader research base—including trials showing reductions in systolic blood pressure and LDL oxidation with pomegranate juice—but Pomanox-specific RCT data remains limited, warranting cautious interpretation.

Nutritional Profile

Pomanox is a standardized pomegranate (Punica granatum) fruit extract characterized by high polyphenol content, typically standardized to contain a minimum of 30% total polyphenols by weight. Key bioactive compounds include: Ellagitannins (primary actives) - punicalagins (alpha and beta isomers, the most abundant ellagitannins in pomegranate, typically comprising 15-20% of the extract), punicalin, and pedunculagin; Ellagic acid - a hydrolysis product of ellagitannins, present at approximately 5-10% concentration, with notable bioavailability as a precursor to urolithins (urolithin A and B) produced by gut microbiota metabolism; Anthocyanins - including delphinidin-3-glucoside, cyanidin-3-glucoside, and pelargonidin-3-glucoside, contributing to antioxidant capacity; Hydrolyzable tannins - including gallic acid derivatives; Flavonoids - luteolin, quercetin, and kaempferol glycosides in minor concentrations. The extract contains negligible macronutrients (protein <1%, fat <1%, carbohydrates minimal at extract concentration). Minerals present in trace amounts include potassium, calcium, and magnesium, though at concentrations too low to contribute meaningfully to daily intake at typical dosages (200-1000 mg/day). Bioavailability notes: Ellagic acid itself has poor systemic bioavailability (~0% intact absorption in some studies), but gut microbiome conversion to urolithins (particularly urolithin A) is considered the primary mechanism of systemic activity; urolithin production is highly individual-dependent based on microbiome composition. Punicalagins exhibit limited direct absorption but exert local antioxidant effects in the GI tract. ORAC (antioxidant capacity) values for the extract are substantially higher than raw pomegranate juice due to concentration. The standardization to polyphenol percentage is the primary quality marker, with Pomanox specifically documented to contain punicalagins as the primary standardization marker.

Preparation & Dosage

Clinically studied doses for Pomanox P30 (standardized to ~30% punicalagins) range from 130 mg to 750 mg per day, corresponding to 40-230 mg punicalagins, with dose-dependent effects based on application. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Resveratrol, Quercetin, Green Tea Extract, CoQ10

Safety & Interactions

Pomanox is generally well tolerated at commonly studied doses of pomegranate extract (typically 400–1000 mg/day), with mild gastrointestinal discomfort such as bloating reported in some users. It may potentiate the effects of antihypertensive medications due to its blood-pressure-lowering properties, and preliminary evidence suggests it can inhibit cytochrome P450 3A4 (CYP3A4), potentially raising plasma levels of drugs metabolized by this enzyme including statins and certain calcium channel blockers. Individuals taking warfarin or other anticoagulants should use caution, as pomegranate polyphenols may influence platelet aggregation and clotting parameters. Safety data in pregnant and breastfeeding women is insufficient, and use during these periods is not recommended without physician supervision.